580 related articles for article (PubMed ID: 33263835)
1. Chimeric antigen receptor T cell therapies for acute myeloid leukemia.
Gu B; Chu J; Wu D
Front Med; 2020 Dec; 14(6):701-710. PubMed ID: 33263835
[TBL] [Abstract][Full Text] [Related]
2. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
[TBL] [Abstract][Full Text] [Related]
3. Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.
Liu J; Zhang X; Zhong JF; Zhang C
Immunotherapy; 2019 Jan; 11(1):37-44. PubMed ID: 30702011
[TBL] [Abstract][Full Text] [Related]
4. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
[TBL] [Abstract][Full Text] [Related]
5. How close are we to CAR T-cell therapy for AML?
Gill SI
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101104. PubMed ID: 31779970
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia.
Trad R; Warda W; Alcazer V; Neto da Rocha M; Berceanu A; Nicod C; Haderbache R; Roussel X; Desbrosses Y; Daguindau E; Renosi F; Roumier C; Bouquet L; Biichle S; Guiot M; Seffar E; Caillot D; Depil S; Robinet E; Salma Y; Deconinck E; Deschamps M; Ferrand C
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35803613
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.
Sommer C; Cheng HY; Nguyen D; Dettling D; Yeung YA; Sutton J; Hamze M; Valton J; Smith J; Djuretic I; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2020 Oct; 28(10):2237-2251. PubMed ID: 32592688
[TBL] [Abstract][Full Text] [Related]
8. Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.
Pratap S; Zhao ZJ
Cancer Rep (Hoboken); 2020 Apr; 3(2):e1222. PubMed ID: 32671999
[TBL] [Abstract][Full Text] [Related]
9. Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease.
Shrestha B; Walton K; Reff J; Sagatys EM; Tu N; Boucher J; Li G; Ghafoor T; Felices M; Miller JS; Pidala J; Blazar BR; Anasetti C; Betts BC; Davila ML
J Clin Invest; 2020 Sep; 130(9):4652-4662. PubMed ID: 32437331
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of chimeric antigen receptor T-cell therapy for acute myeloid leukemia: A subgroup based meta-analysis.
Morsy MM; Azzam AY; Elamin O; Elswedy A; Nashwan AJ
Leuk Res; 2024 May; 140():107498. PubMed ID: 38582045
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
Front Immunol; 2020; 11():580328. PubMed ID: 33384686
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor T cells for acute myeloid leukemia.
Fetsch V; Zeiser R
Eur J Haematol; 2024 Jan; 112(1):28-35. PubMed ID: 37455578
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor T-cell Therapy for Acute Myeloid Leukemia.
Bi X; Hsu J; Gergis M; Yang Y; Yi D; Gergis U
Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):131-136. PubMed ID: 36537909
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia.
Fan M; Li M; Gao L; Geng S; Wang J; Wang Y; Yan Z; Yu L
J Hematol Oncol; 2017 Aug; 10(1):151. PubMed ID: 28851445
[TBL] [Abstract][Full Text] [Related]
15. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in CAR-T cell therapy for acute myeloid leukaemia.
Gao C; Li X; Xu Y; Zhang T; Zhu H; Yao D
J Cell Mol Med; 2024 May; 28(9):e18369. PubMed ID: 38712978
[TBL] [Abstract][Full Text] [Related]
17. Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia.
Limongello R; Marra A; Mancusi A; Bonato S; Hoxha E; Ruggeri L; Hui S; Velardi A; Pierini A
Front Immunol; 2021; 12():695051. PubMed ID: 34413848
[TBL] [Abstract][Full Text] [Related]
18. Adoptive Cellular Therapy in Acute Myeloid Leukemia: Current Scope and Challenges.
Arora S; Asawa P; Ramakrishnan A; Bachier C; Majhail NS
Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):159-167. PubMed ID: 36537907
[TBL] [Abstract][Full Text] [Related]
19. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
Tasian SK; Kenderian SS; Shen F; Ruella M; Shestova O; Kozlowski M; Li Y; Schrank-Hacker A; Morrissette JJD; Carroll M; June CH; Grupp SA; Gill S
Blood; 2017 Apr; 129(17):2395-2407. PubMed ID: 28246194
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia.
Wu G; Guo S; Luo Q; Wang X; Deng W; Ouyang G; Pu JJ; Lei W; Qian W
Front Immunol; 2023; 14():1093750. PubMed ID: 36845088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
